Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 6
2017 7
2018 1
2019 3
2020 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
The Circular RNA Landscape of Non-Small Cell Lung Cancer Cells.
Van Der Steen N, Lyu Y, Hitzler AK, Becker AC, Seiler J, Diederichs S. Van Der Steen N, et al. Cancers (Basel). 2020 Apr 28;12(5):1091. doi: 10.3390/cancers12051091. Cancers (Basel). 2020. PMID: 32353949 Free PMC article.
The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies.
Van Der Steen N, Zwaenepoel K, Mazzaschi G, A Luirink R, P Geerke D, Op de Beeck K, Hermans C, Tiseo M, Van Schil P, Lardon F, Germonpré P, Rolfo C, Giovannetti E, J Peters G, Pauwels P. Van Der Steen N, et al. Molecules. 2019 Dec 4;24(24):4443. doi: 10.3390/molecules24244443. Molecules. 2019. PMID: 31817278 Free PMC article.
Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line.
Van Der Steen N, Leonetti A, Keller K, Dekker H, Funel N, Lardon F, Ruijtenbeek R, Tiseo M, Rolfo C, Pauwels P, Peters GJ, Giovannetti E. Van Der Steen N, et al. Biochem Pharmacol. 2019 Aug;166:128-138. doi: 10.1016/j.bcp.2019.05.014. Epub 2019 May 10. Biochem Pharmacol. 2019. PMID: 31078602
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN.
Cavazzoni A, La Monica S, Alfieri R, Ravelli A, Van Der Steen N, Sciarrillo R, Madeddu D, Lagrasta CAM, Quaini F, Bonelli M, Fumarola C, Cretella D, Digiacomo G, Tiseo M, Peters GJ, Ardizzoni A, Petronini PG, Giovannetti E. Cavazzoni A, et al. Among authors: van der steen n. Oncotarget. 2017 May 23;8(32):53068-53083. doi: 10.18632/oncotarget.18087. eCollection 2017 Aug 8. Oncotarget. 2017. PMID: 28881794 Free PMC article.
Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC.
Van Der Steen N, Mentens Y, Ramael M, Leon LG, Germonpré P, Ferri J, Gandara DR, Giovannetti E, Peters GJ, Pauwels P, Rolfo C. Van Der Steen N, et al. Clin Lung Cancer. 2018 Jan;19(1):35-41. doi: 10.1016/j.cllc.2017.06.010. Epub 2017 Jul 6. Clin Lung Cancer. 2018. PMID: 28757336 Review.
Resistance Mechanisms to AZD9291 and Rociletinib-Letter.
Van Der Steen N, Rolfo C, Pauwels P, de Langen AJ, Peters GJ, Giovannetti E. Van Der Steen N, et al. Clin Cancer Res. 2017 Jul 15;23(14):3966. doi: 10.1158/1078-0432.CCR-17-0167. Clin Cancer Res. 2017. PMID: 28710317 No abstract available.
FGFR a promising druggable target in cancer: Molecular biology and new drugs.
Porta R, Borea R, Coelho A, Khan S, Araújo A, Reclusa P, Franchina T, Van Der Steen N, Van Dam P, Ferri J, Sirera R, Naing A, Hong D, Rolfo C. Porta R, et al. Among authors: van der steen n. Crit Rev Oncol Hematol. 2017 May;113:256-267. doi: 10.1016/j.critrevonc.2017.02.018. Epub 2017 Mar 23. Crit Rev Oncol Hematol. 2017. PMID: 28427515 Review.
20 results